HSIEH, CHING HO,谢清河,謝清河,LIN, YI DONG,林意栋,林意棟,YANG, YU JEN,杨友任,楊友任,YEH, MING LONG,叶明龙,葉明龍
申请号：
TW099112197
公开号：
TWI480069B
申请日:
2010.04.19
申请国别(地区):
TW
年份:
2015
代理人:
摘要：
A pharmaceutical composition for improving myocardial infarction is provided and includes a pharmaceutical composition having a biologically compatible peptide hydrogel formed by a plurality of self-assembling peptide nanofibers and selectively having at least one type of autologous stem cells mixed with the self-assembling peptide nanofibers. The pharmaceutical composition is administered to an entire infarcted area of a myocardium tissue with myocardial infarction by intramyocardial or transendocardial injection. Thus, adverse cardiac remodeling and dysfunction after acute infraction can be attenuated, while the therapeutic myocardial angiogenesis, the myocardial capillary density and potential myogenesis can be enhanced.一種用以改善心肌梗塞之醫藥組成物,其包含一醫藥組成物,其具有一生物相容性胜肽水膠,該水膠係由數個自組裝胜肽奈米纖維共同形成。該醫藥組成物另可選擇具有至少一種自體幹細胞,其混合結合於該自組裝胜肽奈米纖維。該醫藥組成物可經由心肌內或心內膜注射施打至一心肌組織之整個梗塞受損區域內。因此,可減緩有害的心臟重塑及急性心肌梗塞後的功能異常等問題,同時亦可增加心肌微血管密度及促進潛在的心肌新生。1‧‧‧自組裝胜肽奈米纖維2‧‧‧心臟21‧‧‧梗塞受損區域211‧‧‧傳遞位置3‧‧‧自體幹細胞
